GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Alzheimer's & Dementia, Wiley, Vol. 17, No. S1 ( 2021-12)
    Abstract: β‐amyloid PET (Aβ‐PET) is an important tool for quantification of amyloidosis in the brain of suspected Alzheimer’s disease (AD) patients and transgenic AD mouse models. Despite the excellent correlation of Aβ‐PET with gold standard immunohistochemical assessments, the relative contributions of fibrillar and non‐fibrillar Aβ components to the in vivo Aβ‐PET signal remain unclear. Thus, we obtained two murine cerebral amyloidosis models that present with distinct Aβ plaque compositions and performed regression analysis between immunohistochemistry and Aβ PET to determine the biochemical contributions to Aβ‐PET signal in vivo . Method We investigated groups of App NL‐G‐F and APPPS1 mice three, six and 12 months of age by longitudinal [ 18 F]‐florbetaben Aβ‐PET and with immunohistochemical analysis of the fibrillar and total Aβ burdens. We then applied group level inter‐modality regression models using age and genotype matched sets of fibrillar/ non‐fibrillar Aβ data (predictors) and Aβ‐PET results (outcome) for both transgenic models. An independent group of double‐hit APPPS1 mice with dysfunctional microglia due to knock‐out of triggering receptor expression on myeloid cells 2 (Trem2 ‐/‐ ) served for validation and evaluation of translational impact. Result Neither fibrillar nor non‐fibrillar Aβ content alone sufficed to explain the Aβ‐PET findings in either transgenic AD model (Figure 1). A regression model compiling fibrillar and non‐fibrillar Aβ together with the estimate of individual heterogeneity and age at scanning could explain a 93% of variance of the Aβ‐PET signal (p 〈 0.001; Figure 2). Fibrillar Aβ burden had a 16‐fold higher contribution to the Aβ‐PET signal when compared to non‐fibrillar Aβ. However, given the relatively greater abundance of non‐fibrillar Aβ, we estimate that non‐fibrillar Aβ produced 79±25% of the net in vivo Aβ‐PET signal in App NL‐G‐F mice, and 25±12% in the APPPS1 mice. Corresponding results in groups of APPPS1/Trem2 ‐/‐ and APPPS1/Trem2 +/+ mice validated the calculated regression factors and revealed that the altered fibrillarity due to Trem2 knockout impacts the Aβ‐PET signal (Figure 3). Conclusion Taken together, the in vivo Aβ‐PET signal derives from the composite of fibrillar and non‐fibrillar Aβ plaque components. While fibrillar Aβ has inherently higher PET tracer binding, the greater abundance of non‐fibrillar Aβ plaque in AD model mice contributes importantly to the PET signal.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Alzheimer's & Dementia, Wiley, Vol. 16, No. S4 ( 2020-12)
    Abstract: Asymmetries of neuropathology, including amyloid‐β (Aβ) burden, are a well‐known phenomenon in patients with Alzheimer’s disease (AD). Yet the occurrence of asymmetric Aβ deposition in amyloid mouse models of AD is scantly documented. Therefore, we first aimed to investigate Aβ‐asymmetries in a comprehensive study of five different amyloid mouse models examined by Aβ‐ small animal positron‐emission‐tomography (PET). Second, we assessed whether any such asymmetries have an association with microglial activation. Method 523 historical cross‐sectional [ 18 F]‐florbetaben Aβ‐PET scans of five different amyloid mouse models ( App NL‐G‐F , APP‐SL70, PS2APP, APP/PS1, and APPswe) and 27 wild‐type mice were analyzed. 136 of these mice (four models) had also undergone contemporaneous [ 18 F]‐GE‐180 18kDa translocator protein (TSPO)‐PET for microglial activation. The asymmetry index (AI) between the left and the right forebrain was calculated for both tracers. AI values outside the 95%/99% confidence intervals of wild‐type mice were defined as having moderate/strong asymmetry. We also analyzed the AI of Aβ‐PET as a function of age and in correlation with TSPO‐PET AI and calculated extrapolated sample sizes required for analyses of single and combined hemispheres. Result Moderate/strong asymmetries of Aβ deposition were identified in 40%/30% of transgenic mice, occurring most frequently in the PS2APP and App NL‐G‐F models (see Figure 1). A significant left dominance in PS2APP and a significant right hemispheric dominance in APPswe mice were observed for Aβ deposition. There was no age dependency of AI, but there was a significant correlation between AIs of Aβ‐PET and TSPO‐PET (all R 〉 0.3, all p 〈 0.05; Figure 2). Asymmetry was associated with higher variance of SUVR in single hemispheres, leading to higher required sample sizes for a given power (see Figure 3). Conclusion Asymmetry of plaque neuropathology occurs frequently in amyloid mouse models of AD, contributing importantly to variance of results in single hemispheres. Concomitant asymmetry of microglial activation indicates a neuroinflammatory component to hemispheric predominance of fibrillary amyloidosis. Important lateralized distribution of fibrillar plaques has likely been a confounding factor in previous studies with Aβ mouse models and is not sufficiently considered.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...